Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiation Therapy in Localized Bladder Cancer
NCT03419130Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Urothelial Bladder Cancer (UBC), sponsored by University of California, San Francisco. Planned start Jul 2018; status: withdrawn.
02
Drugs
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT03419130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419130.